The post Cynthia Lummis Discusses CLARITY Act With CFTC Chair appeared on BitcoinEthereumNews.com. Senator Lummis held talks with the CFTC chair on advancing theThe post Cynthia Lummis Discusses CLARITY Act With CFTC Chair appeared on BitcoinEthereumNews.com. Senator Lummis held talks with the CFTC chair on advancing the

Cynthia Lummis Discusses CLARITY Act With CFTC Chair

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • Senator Lummis held talks with the CFTC chair on advancing the CLARITY Act.
  • She has advocated for the passage of the CLARITY Act and the use of BTC as a tax-free means of payment.
  • Bank opposition over profit concerns slows bipartisan crypto market bill talks.

Pro-crypto Senator Cynthia Lummis discussed the CLARITY Act with Michael S. Selig, chairman of the U.S. Commodity Futures Trading Commission.

As President Donald Trump reignites the debate over the digital asset market structure bill, Senator Lummis is keen to represent the crypto industry amid significant counterforce from lawmakers affiliated with the traditional banking industry.

“I look forward to continued collaboration as we work to integrate digital assets into the 21st century financial system,” Senator Lummis stated.

Lummis Discusses CLARITY Act With CFTC Leadership

Lummis discussed the CLARITY Act with CFTC leadership as lawmakers work to advance the digital asset market structure bill in the Senate.

Earlier this week, President Trump urged lawmakers affiliated with traditional banks to reach a compromise on stablecoin yield. Moreover, the clause on stablecoin yield has been the main contentious issue, delaying the passage of the digital asset market structure bill in the U.S. Senate.

“Senator Lummis and I are committed to getting market structure across the finish line and delivering clear rules of the road for digital assets, once and for all,” CFTC Chair Selig commented after the meeting.

Similarly, Paul Atkins, Chair of the U.S. Securities and Exchange Commission (SEC), reaffirmed his support for the passage of the CLARITY Act to set clear rules for the broader crypto industry. Atkins stated that he is ready to work closely with CFTC Chair Selig to implement the CLARITY Act in the near future.

Why Clear Crypto Regulations Now? 

The need for clear crypto regulations has gained momentum, with growing calls to protect investors from predatory models. For instance, Senator Lummis stated in a recent CNBC interview that U.S. lawmakers are trying to figure out how people can use Bitcoin as a means of exchange without paying capital gains tax.

Currently, Bitcoin is taxed as property by the Internal Revenue Service (IRS), and its capital gains tax depends primarily on how long an investor held the asset before selling. As such, Senator Lummis is keen to clarify when Bitcoin should be subject to capital gains and when it is used as a simple means of payment, like the U.S. dollar.

The need for clear crypto regulations in the United States has also been advocated to catalyze the mainstream adoption of digital assets, especially the U.S. dollar through stablecoins. 

Related: ‘We Want to Be Dominant in Crypto,’ Trump Says as Market Rallies

Disclaimer: The information presented in this article is for informational and educational purposes only. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses incurred as a result of the utilization of content, products, or services mentioned. Readers are advised to exercise caution before taking any action related to the company.

Source: https://coinedition.com/cynthia-lummis-discusses-clarity-act-with-cftc-chair/

Market Opportunity
The AI Prophecy Logo
The AI Prophecy Price(ACT)
$0.01326
$0.01326$0.01326
+1.92%
USD
The AI Prophecy (ACT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09